映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09606 映恩生物-B

交易中 10-15 11:52:04

158.100

-7.200

-4.36%

最高167.500	最低158.100	成交量54.24万
今开165.000	昨收165.300	日振幅5.69%
总市值144.52亿	流通市值144.52亿	总股本9,141万
成交额8,741万	换手率0.59%	流通股本9,141万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":158.1,"timestamp":1792036320607,"preClose":165.3,"halted":0,"volume":542400,"delay":0,"changeRate":-0.04355716878402914,"floatShares":91409300,"shares":91409300,"eps":-46.669187730022834,"marketStatus":"交易中","change":-7.2,"latestTime":"10-15 11:52:04","open":165,"high":167.5,"low":158.1,"amount":87406920,"amplitude":0.056866,"askPrice":158.3,"askSize":2000,"bidPrice":158.1,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-18.895321057755844,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1792036800000},"marketStatusCode":2,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":165.3,"openAndCloseTimeList":[[1792027800000,1792036800000],[1792040400000,1792051200000]],"volumeRatio":1.54776,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606","defaultTab":"news","newsList":[{"id":"2675118345","title":"映恩生物-B(09606)10月14日斥资348.11万港元回购2.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675118345","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675118345?lang=zh_cn&edition=full","pubTime":"2026-10-14 18:57","pubTimestamp":1791975465,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，于2026年10月14日斥资348.11万港元回购2.1万股;根据于2021年2月28日获采纳并于2023年6月25日修订的首次公开发售前股权激励计划，行使所授予之购股权而发行1.04万股普通股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","LU2543165471.USD","HK0000252160.HKD","09606","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117750310","title":"映恩生物-B：2026年10月14日回购2.1万股，耗资约348.11万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117750310","media":"公告速递","labels":[],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117750310?lang=zh_cn&edition=full","pubTime":"2026-10-14 18:56","pubTimestamp":1791975381,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年10月14日发布的翌日披露报表显示，公司当日于香港联交所场内回购21,000股普通股，约占回购前已发行股本的0.02%。每股回购价格介乎164.20港元至167.00港元，总耗资约348.11万港元。此次股份将作为库存股份持有，相关审批及程序均遵循上市规则与适用法例。此前，公司于2026年6月26日获股东大会批准回购授权，允许回购最多9,058,021股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"映恩生物-B：2026年10月14日回购2.1万股，耗资约348.11万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190909475","title":"异动解读｜映恩生物-B盘中下跌5.09%，港股生物科技板块整体承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1190909475","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190909475?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:38","pubTimestamp":1791941894,"startTime":"0","endTime":"0","summary":"10月14日，映恩生物-B盘中下跌5.09%，报164.6港元，成交额2305.44万港元。当日港股生物科技板块整体走弱，映恩生物-B跌幅与板块压力基本同步。同行个股中，康方生物下跌10.1%，信达生物下跌3.53%，百济神州下跌3.17%，康诺亚-B下跌1.79%，复宏汉霖下跌0.09%。公司此前披露9月股份变动月报，期内因购股权行使新增发行495883股，股本较上月有所增加；叠加上次财报显示上半年收入2.19亿元、经调整净亏损6.27亿元，市场对生物科技板块估值与资金情绪仍偏谨慎。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"映恩生物盘中走弱，生物科技板块承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114439142","title":"异动解读｜映恩生物-B盘中下跌5.18%，港股生物科技板块承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1114439142","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114439142?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:49","pubTimestamp":1791856170,"startTime":"0","endTime":"0","summary":"10月13日，映恩生物-B盘中下跌5.18%，报170.3港元，成交额1781.55万港元。映恩生物-B所在的生物科技行业中，整体呈现弱势，康方生物跌4.2%，百济神州跌2.17%，信达生物跌2.28%，剂泰科技-P跌10.19%，三生制药跌1.36%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司的产品主要用于靶向治疗子宫内膜癌、乳腺癌、小细胞肺癌、去势抵抗性前列腺癌、食管鳞状细胞癌及头颈部鳞状细胞癌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190501442","title":"异动解读｜映恩生物-B盘中下跌5.09%，生物科技板块普遍承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1190501442","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190501442?lang=zh_cn&edition=full","pubTime":"2026-10-08 14:51","pubTimestamp":1791442293,"startTime":"0","endTime":"0","summary":"10月8日，映恩生物-B盘中下跌5.09%，报186.5港元，成交额1.39亿港元。生物科技板块整体走弱，主要同业股价同步下挫，市场风险偏好有所收敛。映恩生物-B所在的生物科技行业中，信达生物下跌4.87%，康方生物下跌3.48%，百济神州下跌1.94%，三生制药下跌4.71%，康希诺生物下跌3.42%。板块性调整或为本次股价下跌的主要背景。公司是一家全球性的临床阶段生物制药公司，致力于发现及开发下一代抗体偶联药物疗法，用于癌症和自身免疫性疾病等患者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103359598","title":"映恩生物-B更新2026年9月股份变动月报，新增495,883股","url":"https://stock-news.laohu8.com/highlight/detail?id=1103359598","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103359598?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:46","pubTimestamp":1791362777,"startTime":"0","endTime":"0","summary":"2026年10月7日，映恩生物-B发布截至2026年9月30日的证券变动月报。公告显示，本月公司法定/注册股本保持不变，仍为2亿股普通股，面值0.0001美元，合计注册股本为2万美元。报告期内，映恩生物-B已发行股份由90,833,614股增加至91,329,497股，较上月底增发495,883股，库存股份数量仍为400,100股，因此已发行股份总数增至91,729,597股。其中，当月因期权行使实际增发495,883股，同时注销34,784份期权。截至2026年9月30日，映恩生物-B的股本规模较上月有所增加。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165105519","title":"映恩生物-B：9月29日新增发行78,100股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1165105519","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165105519?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:26","pubTimestamp":1790688371,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年9月29日发布翌日披露报表。公告称，公司依据2021年2月28日采纳并于2023年6月25日修订的首次公开发售前股权激励计划，于9月29日因非公司董事与公司董事分别行使购股权，合计发行普通股78,100股。其中，非公司董事行使购股权所发行18,100股普通股，占变动前已发行股本约0.02%，发行价为每股201.1497港元；公司董事行使购股权所发行60,000股普通股，占变动前已发行股本约0.07%，发行价为每股201.2782港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"映恩生物-B：9月29日新增发行78,100股股份","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671632217","title":"映恩生物-B(09606)因购股权获行使合计发行7.81万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2671632217","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671632217?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:23","pubTimestamp":1790688198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，根据于2021年2月28日获采纳并于2023年6月25日修订的首次公开发售前股权激励计划，行使所授予的购股权而发行1.81万股普通股。根据于2021年2月28日获采纳并于2023年6月25日修订的首次公开发售前股权激励计划，行使所授予的购股权而发行6万股普通股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","BK1161","HK0000252152.HKD","09606","HK0000252160.HKD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155145105","title":"异动解读｜映恩生物-B盘中上涨5.34%，ESMO大会临近叠加生物科技板块集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1155145105","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155145105?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:55","pubTimestamp":1790646953,"startTime":"0","endTime":"0","summary":"9月29日，映恩生物-B盘中上涨5.34%，报205.2港元，成交额2941.37万港元。消息面上，ESMO年会将于10月下旬在马德里举行，最新公布的突破性摘要名单中，中国来源临床研究达32项、占比超三成，ADC管线密集亮相预期升温。此前映恩生物与罗氏旗下Genentech达成全球ADC合作协议，首付款4500万美元、潜在里程碑超10亿美元；公司核心管线DB-1311联合数据亦在WCLC大会披露，IO2.0+ADC方向获行业关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物强势上涨，ESMO催化ADC行情","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670230165","title":"映恩生物-B(09606)因购股权获行使合计发行约39.97万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670230165","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670230165?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:05","pubTimestamp":1790600722,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，于2026年9月1日至9月28日，根据于2021年2月28日获采纳并于2023年6月25日修订的首次公开发售前股权激励计划，行使所授予的购股权而发行约39.97万股普通股。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["HK0000252152.HKD","HK0000500386.USD","09606","HK0000252160.HKD","BK1161","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182361225","title":"映恩生物-B于9月28日新增约39.97万股已发行股份，涉资约7,795.98万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182361225","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182361225?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:04","pubTimestamp":1790600682,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年9月28日刊发翌日披露报表。公告显示，自2026年9月1日至9月28日期间，公司因根据其2021年2月28日采纳并于2023年6月25日修订的首次公开发售前股权激励计划行使购股权，共计发行新股399,683股，约占公司此前已发行股本的0.44%。发行价格介乎每股166.7265港元至214.4624港元，合计涉资约7,795.98万港元。公司同时确认，所有股份发行已获董事会正式授权，并遵守香港联合交易所有限公司证券上市规则及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"映恩生物-B于9月28日新增约39.97万股已发行股份，涉资约7,795.98万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110882219","title":"映恩生物-B 2026年中期营收2.19亿元，经调整净亏损6.27亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110882219","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110882219?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:57","pubTimestamp":1790596631,"startTime":"0","endTime":"0","summary":"映恩生物-B披露2026年中期财务报告。报告期内，收入为2.19亿元，同比下降82.20%。经调整净利润从上年同期的1.46亿元转为亏损6.27亿元，同比下降529.60%。研发开支为6.07亿元，同比增长73.60%。行政开支从上年同期的1.26亿元下降到0.82亿元，同比下降35.10%。经营活动产生的现金流从上年同期的5.90亿元减少到-4.24亿元，同比下降172.00%。映恩生物愿以自身探索与实践，为中国创新药融入全球产业链贡献绵薄之力，为更多患者带来治疗希望。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"映恩生物-B 2026年中期营收2.19亿元，经调整净亏损6.27亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147890373","title":"异动解读｜映恩生物-B盘中下跌5.02%，报204.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1147890373","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147890373?lang=zh_cn&edition=full","pubTime":"2026-09-24 10:09","pubTimestamp":1790215779,"startTime":"0","endTime":"0","summary":"9月24日，映恩生物-B盘中下跌5.02%，报204.2港元/股，成交额3023.1万港元。映恩生物-B所在的生物科技行业整体走弱，个股中，康方生物跌3.44%，信达生物跌3.58%，百济神州跌1.47%，荣昌生物跌5.58%，三生制药跌3.64%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310等，覆盖子宫内膜癌、乳腺癌、小细胞肺癌等多个适应症。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188227323","title":"创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188227323","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188227323?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:01","pubTimestamp":1790132509,"startTime":"0","endTime":"0","summary":"9月23日，创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%，康方生物、诺诚健华涨逾3%，基石药业涨逾2%，百济神州、药明生物、君实生物涨逾1%，信达生物跟涨。9月12-15日2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3 ADC等成为焦点；与此同时，2026年国家医保目录谈判收官，商保创新药目录同步推进，支付端改革预期升温，\"出海商业化+支付改善\"的产业逻辑持续强化。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","06618","02268","06978","09966","01801","00241","02137","03347","06606","02269","06622","06996","09688","09606","02359","03759","09995"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1170311123","title":"异动解读｜映恩生物-B盘中上涨5.24%，DB-1311联合方案一线SCLC ORR达92.3%持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1170311123","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170311123?lang=zh_cn&edition=full","pubTime":"2026-09-18 11:31","pubTimestamp":1789702306,"startTime":"0","endTime":"0","summary":"9月18日，映恩生物-B盘中上涨5.24%，报192.9港元，成交额1.03亿港元。消息面上，近日世界肺癌大会更新了映恩生物与BioNTech共同开发的B7-H3 ADC DB-1311/BNT324联合PD-L1×VEGF-A双抗Pumitamig治疗晚期肺癌的Ib/II期临床数据：71例可评估小细胞肺癌患者整体客观缓解率达70.4%，其中一线ORR高达92.3%、二线77.3%、三线及以上52.4%，数据表现亮眼，持续提振市场情绪。映恩生物是一家临床阶段生物制药公司，致力于研发覆盖肿瘤与自身免疫性疾病的抗体偶联药物创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物盘中上涨，一线肺癌数据亮眼","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100752322","title":"异动解读｜映恩生物-B盘中上涨10.55%，DB-1311联合方案一线SCLC ORR达92.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100752322","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100752322?lang=zh_cn&edition=full","pubTime":"2026-09-14 14:50","pubTimestamp":1789368640,"startTime":"0","endTime":"0","summary":"9月14日，映恩生物-B盘中上涨10.55%，报186.5港元，成交额1.87亿港元。消息面上，世界肺癌大会更新了映恩生物与BioNTech共同开发的B7-H3 ADC DB-1311/BNT324联合PD-L1×VEGF-A双抗Pumitamig治疗晚期肺癌的Ib/II期临床数据：截至7月7日，71例可评估小细胞肺癌患者整体客观缓解率为70.4%，其中一线ORR高达92.3%、二线77.3%、三线及以上52.4%，数据表现亮眼。映恩生物是一家临床阶段生物制药公司，致力于研发抗体偶联药物，覆盖肿瘤与自身免疫性疾病领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物大涨，一线小细胞肺癌数据亮眼","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658657","title":"港股异动 | 映恩生物-B涨超9%，DB-1311联用Pumitamig WCLC摘要披露，一线SCLC ORR达92.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658657","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667658657?lang=zh_cn&edition=full","pubTime":"2026-09-14 14:38","pubTimestamp":1789367907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超9%，截至发稿，涨8.48%，报183港元，成交额1.65亿港元。消息面上，世界肺癌大会更新了映恩生物与BioNTech共同开发的B7-H3 ADC BNT324/DB-1311联合PD-L1×VEGF-A双抗Pumitamig治疗晚期肺癌的Ib/II期数据：截至2026年7月7日，71例可评估小细胞肺癌患者整体客观缓解率为70.4%，其中一线92.3%、二线77.3%、三线及以上52.4%。","market":"sh","thumbnail":"https://community-static.tradeup.com/news/b772ac54294987140db862d7556db12e","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/b772ac54294987140db862d7556db12e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495543.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物 DB-1311联用Pumitamig WCLC摘要披露，一线SCLC ORR达92.3%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2543165471.USD","09606","HK0000252160.HKD","HK0000500386.USD","BK1161","BK4588","VXUS","KCAI","ORR","HK0000252152.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144991606","title":"异动解读｜映恩生物-B盘中下跌5.38%，生物科技板块集体承压叠加中期业绩承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1144991606","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144991606?lang=zh_cn&edition=full","pubTime":"2026-09-10 10:20","pubTimestamp":1789006810,"startTime":"0","endTime":"0","summary":"9月10日，映恩生物-B盘中下跌5.38%，报174.0港元，成交额7780.66万港元。消息面上，公司此前披露的中期业绩显示，上半年营收2.19亿元，较上年同期的12.29亿元大幅下滑，经调整净亏损6.27亿元，经营活动现金流由上年同期净流入5.90亿元转为净流出4.24亿元。此外，生物科技板块今日整体走弱，行业个股中云顶新耀跌7.82%、三生制药跌3.16%、信达生物跌2.49%、康方生物跌0.79%、百济神州跌0.67%，板块系统性回调亦对股价形成拖累。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"映恩生物盘中下跌，生物科技板块集体承压","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161734352","title":"映恩生物-B：DualityBio Ltd.增持，好仓比例升至7.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161734352","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161734352?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:52","pubTimestamp":1788861153,"startTime":"0","endTime":"0","summary":"DualityBio Ltd.于2026年9月2日以每股均价174.054港元买入映恩生物-B股份1.00万股，涉资约174.05万港元。DualityBio Ltd.此次增持前持有映恩生物-B好仓655.50万股，占比7.18%；增持后持股量为656.50万股，好仓比例升至7.19%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187354305","title":"映恩生物-B：DualityBio Ltd.增持，好仓比例升至7.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187354305","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187354305?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:16","pubTimestamp":1788859002,"startTime":"0","endTime":"0","summary":"DualityBio Ltd.于2026年9月3日以每股均价184.149港元买入映恩生物-B股份1.00万股，涉资约184.15万港元。DualityBio Ltd.此次增持前持有映恩生物-B好仓656.50万股，占比7.19%；增持后持股量为657.50万股，好仓比例升至7.2%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":-0.1588},{"period":"1month","weight":-0.1108},{"period":"3month","weight":-0.3031},{"period":"6month","weight":-0.4678},{"period":"1year","weight":-0.458},{"period":"ytd","weight":-0.4457}],"compareEarnings":[{"period":"1week","weight":0.0076},{"period":"1month","weight":-0.0242},{"period":"3month","weight":-0.0278},{"period":"6month","weight":-0.0706},{"period":"1year","weight":-0.0443},{"period":"ytd","weight":-0.0514}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}